BIO-B — Bio-Rad Laboratories, Inc.

Bio-Rad Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Sales: Approximately $693 million, a 3.9% increase year-over-year (YoY) from $668 million in Q4 2024.
• Life Science Segment Sales: $268 million, down 2.6% YoY from $275 million in Q4 2024.
• Clinical Diagnostics Segment Sales: $425 million, up 8.4% YoY from $393 million in Q4 2024.
• GAAP Gross Margin: 49.8%, down from 51.2% in Q4 2024; Non-GAAP Gross Margin: 52.5%, down from 53.9%.
• Operating Loss: Approximately $119 million in Q4 2025, compared to operating income of $58 million in Q4 2024.
• Full Year 2025 Net Sales: $2.583 billion, a 0.7% increase from $2.567 billion in 2024.
• Non-GAAP Net Income: $271 million or $9.92 diluted EPS for 2025, down from $291 million or $10.31 diluted EPS in 2024.
• Free Cash Flow: $375 million for 2025, up from $290 million in 2024.

2. Strategic Updates and Business Highlights

• Diagnostics Segment Growth: Driven by successful fulfillment of large orders and improved demand for quality control products.
• Life Science Segment: Positive traction from the Stilla acquisition and the QX700 Droplet Digital PCR (ddPCR) product line, with strong customer response.
• Operational Improvements: Initiatives to enhance forecasting, planning, and operational rigor were emphasized to mitigate supply chain challenges.
• Focus on Innovation: Plans for product launches in 2026, including an IVD version of the QX600 and additional ddPCR assays.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected currency-neutral growth of 0.5% to 1.5%. Q1 is anticipated to decline low single digits YoY, with sequential improvement expected throughout the year.
• Life Science Segment Growth: Projected to grow 0% to 0.5%, with core Life Science (excluding process chromatography) expected to grow nearly 4%.
• Diagnostics Segment Growth: Estimated currency-neutral growth of 1% to 2%.
• Gross Margin Guidance: Projected to be between 54% and 54.5% for 2026, with operational improvements anticipated.
• Free Cash Flow: Expected to be approximately $375 million to $395 million for 2026.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressure: Q4 gross margin was negatively impacted by higher supply chain costs and operational inefficiencies.
• Life Science Segment Decline: Overall sales in the Life Science segment decreased, primarily due to constrained academic research funding and biopharma market softness.
• Process Chromatography Outlook: Anticipated to decline mid-teens in 2026 due to regulatory changes and customer production efficiencies, with a long-term growth forecast of mid-single digits.
• Operational Challenges: Higher-than-expected expenses related to expedited freight and service costs due to compressed timelines for instrument delivery.

5. Notable Q&A Insights

• ddPCR Business Growth: Strong sales in the QX700 platform were highlighted, with a shift in revenue contribution from assays to instruments.
• Process Chromatography Concerns: Changes in customer manufacturing strategies due to vaccine demand shifts were discussed, with a cautious outlook on recovery.
• Lack of Buybacks: The absence of share repurchases in Q4 was clarified as an opportunistic approach, with ongoing M&A considerations.
• Long-term Growth Projections: The management expressed optimism about stabilization in core markets and the potential for improved funding conditions in biopharma and academia.

Overall, Bio-Rad's Q4 2025 results reflect a mix of growth in diagnostics, challenges in life sciences, and a cautious yet optimistic outlook for 2026 amidst ongoing operational improvements and strategic initiatives.